Form 4: Vaxcyte SVP, General Counsel & Corp Sec Mikhail Eydelman Reports Stock Sales
SEC Form 4
Mikhail Eydelman, SVP, General Counsel & Corp Sec of Vaxcyte, Inc., reported the sale of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 1, 2024, Mikhail Eydelman, the SVP, General Counsel & Corp Sec of Vaxcyte, Inc. (PCVX), executed multiple transactions involving the company's common stock.
- Eydelman exercised stock options to acquire 1,667 shares at a price of $21.41.
- Simultaneously, Eydelman sold a total of 1,667 shares in four separate transactions at weighted-average prices ranging from $61.297 to $63.903.
- These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 29, 2023.
- Following these transactions, Eydelman directly owns 30,597 shares of Vaxcyte common stock and holds options for 186,665 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions by an insider under a pre-existing trading plan. There's no indication of positive or negative implications for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The impact on Vaxcyte's stock will likely be minimal unless these transactions are unusually large or frequent.
Key Dates
| Date | Description |
|---|---|
| 2023-04-01 | 1/4 of the shares subject to the option shall vest |
| 2023-06-29 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-05-01 | Date of stock option exercise and sales |
| 2032-05-08 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.